“Four months after its creation, TreeFrog Therapeutic announces license agreement with tech transfer office Aquitaine Science Transfert to industrialize and commercialize a breakthrough technology based on 3D cell culture. Newly headquartered at the ENSTBB, on the campus of Bordeaux, the start-up aims at providing the pharmaceutical industry with a solution to mass-produce stem cells, reducing costs and introducing an unprecedented quality standard. Protected by seven patents from the University of BordeauxCNRS and the Institut d’Optique Graduate School, TreeFrog’s technology will enable millions of patients with degenerative diseases or waiting for organ transplantation, to access the medical revolution of cell therapies.”

Read the Press Release (in French)